SUSUMU SATO, Vice President
received his B.A. from Doshisha University, a prestigious private
university in the Kansai region, where he majored in Economics,
specializing in Japanese economic history.
graduating from the university in 1969, Sato went to work for
a small chemical company in Osaka, where he became the Controller
and a Director and was responsible for difficult cost-cutting
initiatives---including closure of a local manufacturing facility
and establishment of an off-shore plant in Korea---which returned
the company to profitability.
1978 Sato went to work for Japan Travenol Limited (“JTL”)
a joint venture of Baxter Travenol Laboratories (now Baxter
International, Inc., hereinafter “Baxter”) and Sumitomo
Chemical. There he was responsible for relocating the manufacturing
operations from a Sumitomo facility in Osaka to a newly established
plant in Gifu, which plant Sato helped to plan and establish
and where he served as Controller during the transition. After
relocating with his family to Tokyo, Sato worked with the finance
team that helped Baxter acquire 100% ownership of JTL and complete
other consolidation tasks, establishing Baxter’s wholly
owned subsidiary, currently named Baxter Limited, K.K. (“Baxter
was a member of the team that originally established the Dialysis
Division of Baxter Limited and, then, successfully introduced
continuous ambulatory peritoneal dialysis (CAPD) products in
Japan. He later did much of the planning and financial analysis
which led to Baxter’s $40 million investment in a new
CAPD solutions manufacturing facility in Miyazaki Prefecture.
also served briefly in the Office of the President of Baxter
Limited and helped to establish and manage the company’s
New Business Development Department. Following the acquisition
of American Hospital Supply Corporation by Baxter, Sato was
named Chairman of the Post-merger Consolidation Task Force in
Japan, established to plan and implement local consolidation
of Baxter Limited with American Hospital Supply Japan.
prior to leaving Baxter to co-found CTG, Sato was Bucho
responsible for all non-sales divisions of Baxter’s Global
Renal Therapy Business in Japan.
is presently Representative Director of CTG, K.K. and ev3,K.K.
He was previously a Director of ResMed, K.K. and Total Renal
Care Japan, K.K. and a Statutory Auditor (Kansayaku) of
ev3, K.K., Aksys Japan, K.K., MediSense K.K., Nova Biomedical,
K.K., and ESC Medical Systems, K.K.